Human HDAC9 , GenBank Accession No. NM_178423, a.a. 604-1066 with C-terminal His-tag, MW= 50.7 kDa, expressed in baculovirus expression system.

Q9UKV0

histone deacetylase 9, HDAC-9

≥3000 pmol/min/µg

25 mM Tris HCl, pH 8.0, 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl₂, and 0.1 mg/ml BSA, 20 µM BPS HDAC class 2a substrate (Catalog #50040), and HDAC9 (0.15 - 10 ng). Incubation condition: 30 min at 37°C, followed by HDAC developer (Catalog #50030) for 15 min at room temperature. Fluorescence intensity is measured at ex360/em460.

40 mM Tris-HCl, pH 8.0, 110 mM NaCl, 2.2 mM KCl, 20% glycerol, 200 mM imidazole

Aqueous buffer solution

>6 months at -80°C.

Useful for the study of enzyme kinetics, screening inhibitors, and selectivity profiling.

1. Han et al., (2005) J.Mol. Biol. 345, 91-102
2. Lomonte et al., (2004) J. Virol 78, 6744-6757.

Application References:
1. An azumamide C analogue without the zinc-binding functionality (2017)
2. Design, synthesis, 3D pharmacophore, QSAR, and docking studies of carboxylic acid derivatives as Histone Deacetylase inhibitors and cytotoxic agents (2014)
3. In Vivo Imaging of Histone Deacetylases (HDACs) in the Central Nervous System and Major Peripheral Organs (2014)
4. The effect of various zinc binding groups on inhibition of histone deacetylases 1-11 (2014)
5. A selective HDAC 1/2 inhibitor modulates chromatin and gene expression in brain and alters mouse behavior in two mood-related tests (2013)
6. Crebinostat: a novel cognitive enhancer that inhibits histone deacetylase activity and modulates chromatin-mediated neuroplasticity (2013)
7. FDG-PET imaging reveals local brain glucose utilization is altered by class I histone deacetylase inhibitors (2013)
8. Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group (2013)

Avoid freeze/thaw cycles.

Deacetylase

Recombinant Protein